[Reprint] medicine 10 rare variety _ pistachio _ Sina Blog

ԭ�ĵ�ַ��ҽҩ10��ϡsan francisco personal injury attorneys ȱƷ�����ߣ��ɸ�wbr>��Ԫbill consolidation loan mortgage second Ӣ��νϡȱƷ�֣�������Ϊ��˾��Ʒ�Ķ����ԡ������ԡ��޾����ԣ�Ҳ�������г��߳�injury lawyers orlando�ֵIJ��ԣ������Dz��ʼ۸������ Any varieties require good prices. Located Huang 600436 main raw materials of musk, increasing natural resource scarcity bezoar, product supply and poor rendering increasing trend. Thus, located Huang's unique effectiveness and market hunger State will inevitably formed price ascending channel, but as a non-essential drugs and medical insurance varieties of exclusive products, located Huang pricing without the need for national development and Reform Commission and the food and Drug Administration approval, only need to report to the provincial Department of prices, to a large extent avoid drug price policy, future price increases expected clear phases and frequency may increase. Exporting company overseas agent contract for three years at the end of this year to consider in product price net difference has reached more than $ 40, next year overseas product price increases probability is very high. Golden sugar better a company take a decade of research and development of pure herbal products, and is currently the only mechanism on explicit treatment of type II diabetes varieties (utility component to 1-deoxynojirimycin), its efficacy and II diabetes mainly Western varieties acarbose very close but no obvious adverse effect of gastrointestinal tract, in China's existing adult diabetes patients up to 9 million and annual incidence of 9.7% increments the patient population, Golden sugar Ning is expected with proprietary features advantages gradually become the company's future line of varieties. If as scarce species located Huang undoubtedly should be first. Donge ejiao 000423 ejiao exclusive herbal medicine in 2000, when the Ming and Qing dynasties donkey-hide gelatin 4000-6000 Yuan/kg, the current market is $ 400, catty, seen price increases space, have control over the national donkey skin resources 90 per cent of the market share of up to 75%. A truly scarce resources monopoly enterprises, full pricing right, typical of scarce species. Tian Li Shi 600535 China's future trend is ageing, now 10 people in one man, four or five years is 5 people in one man, middle-aged most susceptible is cardiovascular disease, and Salvia is the treatment of cardiovascular disease by a brother, will maximize the enjoyment of the ageing of the market, and the cake dripping pills is entering the United States, enter the international market can be said to be a model for modernization of traditional Chinese medicine, the inclusion of rare varieties and not excessive. Guizhou bailing 002424 here news: Huang Ping County a bowl of water country long Hu village MUI farong, 130 acres of wasteland this year contract cultivation pseudostellaria heterophylla, by average 180 Yuan/kg price sale, profit from 300 million Yuan, became the County's "King" pseudostellaria heterophylla enrichment. 689 pseudostellaria heterophylla prices this year, up to 300 kg, and a farmer $ independent bucket 1 acre of land can earn 2.3 $ bailing if intensive cultivation, 1 million mu of land could contribute 2 billion profit. See "Purple Xin pharmaceutical", genseng industry a month stock price doubled last year, profit before! bailing 1.1 billion, the project will be able to make profits increase two times (Guizhou bailing wholly-owned subsidiary of Guizhou bailing group pharmaceutical sales co., Ltd. November 11 and Guizhou province shibing County Government signed the traditional cooperation development project intention agreement, the parties have decided to jointly shibing County construction efforts in occupies an area of about ten thousand mu of pseudostellaria heterophylla planting demonstration base, and to meet labour and production costs, and other forms of delegated jurisdiction shibing County in Guizhou ternary too Po industrial co., Ltd. planting. Pharmaceutical distribution company will invest 50 million Yuan for that matter), coupled with the company for the first unit of the Miao medicine, trends and prospects for the middle is very optimistic about the company. Chongqing beer 600132 170 more earnings why still investment value? become familiar with and buy heavy beer, no one is watching it's beer, were fastened on the treatment of hepatitis b vaccine. Hepatitis b vaccine, if successful, then the comparison is now used in the treatment of hepatitis b drug, treatment of a person not less than 500-1000 Yuan, annual yield in one million copies, it is 50-100 billion, excluding sales costs and cost, profit is greater than 50 per cent of 15-50 billion yuan, the total share capital is less than 5 million,Profit per share was $! 3 to 10 playing heavy beer is the national 1.3 billion people dream, hope of all family members, how much you value? treatment of hepatitis b vaccine if successful, the Chongqing beer will be the two most scarce species also have become two of the most expensive stocks. Wuhan Jianmin 600973 bezoar is highly respected in the Chinese medicine practitioners to indulge in luxury traditional Chinese medicine, because of its special effect, use very broad. In a variety of herbs, 4500 with bezoar constituents have 600 variety. According to conservative estimates that approximately natural bezoar market 100 billion or so in size. Currently on the market, the majority of non-natural calculus Bovis. As the natural beach of bezoar price, usually in your 10-20 Yuan/kg, unscrupulous traders of counterfeit goods flooded the market. 2009 new "health reform" programme implementation, drug administration into focus, it is expected that the future of the country's market will bezoar strategy and purified. The company earlier intervention in vitro Bovis projects in recent years the company mergers and acquisitions to resolve competition, seeking strategic support, as well as through joint marketing, and to further improve market share. With the price and sales volume while prices and specifications, Niu-market companies in vitro Bovis project may be given the explosive growth.��Because Jianmin is the only company that owns the bezoar, bezoar is scarce resources then Wuhan Jianmin, of course, is a rare breed. Yu Heng-pharmaceutical 002437 next 1-3 years product line promises to leaps: adhere to the "varieties is King", future product line will significantly enrich the: 1) cefminox: acquired Japan Meiji (Medicare) trademark licensing, priced separately. 2) ginkgolide B injection: (TCM new drug in a class, cardiovascular disease), the Ginkgo single agent first, is expected to become the company a 100 million main varieties. 3) other: Qin qinlongkusu injection (traditional Chinese medicine, a class of drug-induced liver disease), MED02 (a class of drugs, tumor), etc. Yu Heng-marketing model incorporates agent system and Terminal system features two modes, formed on agents "boutique style" management of special mode, channels control ability is strong, the past few years has been using cash sales. 2010 is the year of the company's expansion, better growth is expected to start from 2011, 2012, is likely to face a larger outbreak. Company exclusive deer polypeptide injection (Xin Mei Lok) term of protection for up to 20 years. 2010 October 11 Yu hang a paper notice, that is purchased the leukemia drug patents, if Yu Heng in late access to food and Drug Administration approval and listing of curative success, I believe this is a piece of the action event! but it is expected that this process takes at least 3-5 years was also me query! leukemia market space is amazing, as follows: my leukemia incidence 2.76/10 million. In the cancer death rate in occupies six leukemia (male) and 8 bit (female), my 10-year-old following childhood leukemia incidence 2.28/10 million. According to the Ministry of health in the 2008 statistical year check on my leukemia die rates only 3.84/10 million as per person and treatment cost of $ 20 million; the market space of about 70 billion business space. This unit is to stay more valuable and therefore classified as rare species. Double luyao industry 002038 company product lines generally revolves around three areas to build that cancer, liver disease and cardiovascular disease, medication, three types of disease morbidity and mortality in our country is in the forefront, have broad market space. Biocoen: new Medicare will promote 11 years of strong growth in sales; once in the Beijing area four drug tender to the beginning of this year, the product is expected to enter into force more than outside hospitals, the new hospital is expected 2011 Beijing market growth is also expected to be super: Company reserves rich products, future potential is enough: the company there are monoclonal antibody drugs, long standing Synbiotics, 818, product research and development of future uphold reserves, mainline in the biopharmaceutical field bigger and stronger, the unit can be said to be the most worth Middle biopharmaceutical investment of scarce species, can be said to be China's gene Tektronix. Violet ancient Chinese 000590 ancient Chinese health actuarial formula is derived from two thousand years the Mawangdui Han, unearthed two thousand years ago female Mummy unearthed and not rot, modern biotechnology can do, along with unearthed health party preparation of ancient Chinese health-preserving fine pieces more than 20 years of market test, on the real health and health effects of excellence. In the case of national treasure top secret health party State secret project, the whole of China, only this one, the world's only this one is the scarcity of scarce resources, comparable donkey-hide gelatin and China rare earth. Before the Spring Festival in Mount 4 billion equity return, branch health actuarial/year in the production and launch phase of CCTV advertising will enable the unit full of suspense, it can be said that the unit is a health food scarce species. CITIC guojian currently monoclonal antibody market size of over $ 1 billion every year to more than 50% of the speed of high growth. Our monoclonal antibody industry began to Roche and Merck's heavyweight several foreign capital into the monoclonal antibody drugs, but then a hundred Thai biological and CITIC guojian several domestic manufacturers of monoclonal antibody products to market, quickly opened the market. Monoclonal antibody drugs is a piece of the pharmaceutical industry of blue ocean, so as long as they have effect obvious, strong product launch can rapidly become a heavyweight drugs. ����ҩ�����Ҫ����֮One is its culture to enlarge production technology, CITIC alive first resolved the mass production of monoclonal antibodies of industrialization challenges. Company in 2006 listing of monoclonal antibody drugs yisaipu, due to the treatment of moderate and severe active rheumatoid arthritis have very obvious effect, since the market has been growing rapidly, after 4 years after sales of nearly $ 300 million. The company now has the most complete home system in monoclonal antibody drugs reserves, and will build on the scale of the rapid development of the monoclonal antibody production technology, complete gene Tektronix-growth curve. Domestic monoclonal antibody research product line is the most abundant are the CITIC guojian, the company's total investment of over $ 1 billion, with strong financial and technical strength. CITIC guojian will soon be in A stock market listing, the listing of CITIC workhorse with capital market forces rapidly, will become A stock market and a leading biopharmaceutical company. Therefore the column view in all of scarce coins listed will soon be in CITIC kin is scarce coins of scarce species.